Purpose: Neuroendocrine prostate cancer (NEPC) is a resistance phenotype that emerges
in men with metastatic castration-resistant prostate adenocarcinoma (CR-PRAD) and has …

Castration-resistant prostate cancer (CRPC) is a heterogeneous disease associated with
phenotypic subtypes that drive therapy response and outcome differences. Histologic …

Introduction The current methodology involving diagnosis of prostate cancer (PCa) relies on
the pathology examination of prostate needle biopsies, a method with high false negative …

Loss of androgen receptor (AR) signaling dependence occurs in approximately 15%–20%
of advanced treatment-resistant prostate cancers, and this may manifest clinically as …

Prostate cancer (PCa) is among the most common cancers in men worldwide [1] and
comprises a highly heterogenous disease, which ranges from indolent localized cancer to …

BACKGROUND Prostate cancer (PCa) diagnosis is challenging because efforts for effective,
timely treatment of men with significant cancer typically result in over‐diagnosis and repeat …

Purpose Detection of DNA hypermethylation has emerged as a novel molecular biomarker
for prostate cancer diagnosis and evaluation of prognosis. We sought to define whether a …

Novel and minimally-invasive prostate cancer (PCa)-specific biomarkers are needed to
improve diagnosis and risk stratification. Here, we investigated the biomarker potential in …

Although prostate cancer (PCa) is the second leading cause of cancer death among men
worldwide, not all men diagnosed with PCa will die from the disease. A critical challenge …

BACKGROUND A prostate cancer (PCa) biomarker with improved specificity relative to PSA
is a public health priority. Hypermethylated DNA can be detected in body fluids from PCa …